Physician profile
Brent Black
NPI 1710927835
$2,712.85
in general payments reported to CMS, 2019-2025
34 companies · $22.79 in 2025
The $22.79 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $144 · 2021: $674 · 2022: $944 · 2023: $376 · 2024: $14.52 · 2025: $22.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $262.79 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $238.42 | 2019-2023 | |
| Glaxosmithkline, LLC. | $217.18 | 2019-2023 | Trelegy Ellipta, Shingrix, Boostrix |
| Merck Sharp & Dohme LLC | $164.75 | 2019-2022 | |
| Abbvie INC. | $164.30 | 2021-2025 | Qulipta, Vraylar |
| Esperion Therapeutics, INC. | $163.79 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $134.47 | 2019-2022 | |
| Astellas Pharma US INC | $129.05 | 2020-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $121.91 | 2019-2022 | |
| Amgen INC. | $118.82 | 2019-2023 | Repatha, Otezla |
| Ge Healthcare | $115.97 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.60 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $99.87 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $87.11 | 2019-2022 | |
| Amarin Pharma, INC. | $79.21 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $63.65 | 2021-2022 | |
| Abiomed | $58.33 | 2023 | Impella |
| Sanofi-Aventis U.S. LLC | $49.70 | 2019 | |
| Boston Scientific Corporation | $41.20 | 2023 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.81 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.66 | 2021 | |
| Mylan Specialty L.P. | $21.37 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.46 | 2022 | |
| Daiichi Sankyo INC. | $18.63 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.25 | 2022 | |
| Almatica Pharma LLC | $16.93 | 2022 | |
| Redhill Biopharma INC. | $16.72 | 2022 | |
| Aytu Biopharma, INC. | $15.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.85 | 2022 | |
| Abbott Laboratories | $14.52 | 2024 | Jot Dx |
| Biogen, INC. | $14.22 | 2021 | |
| Allergan, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.